Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9390-9392
10.1182/blood-2022-159001